NRI Secure Launches Japan's First "Blockchain Assessment" Service
NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/
Overview of the "Blockchain Assessment" Service (Graphic: Business Wire)
As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or even to actual damage*4 by causing services to behave differently than originally intended.
In response to these issues, NRI Secure has systematized its accumulated knowledge and insights in the form of the “Blockchain Assessment” service. As its first step, NRI Secure will be launching the security assessment service for smart contracts. The service performs assessment from the dual perspectives of static analysis, which carefully analyzes a program, and dynamic analysis, which involves simulating a real attack, in order to identify vulnerabilities.
More assessment menus for other constituent elements of the blockchain will be added in the future. (2 to 4 in the overview diagram). This service is only available in English and Japanese.
NRI Secure continues to provide a variety of products and services for supporting companies and organizations in their information security measures, and to contribute to the creation of a safe information system environment and society on a global scale.
|*1||First-ever in Japan: This is the first security assessment service designed specifically for the blockchain to be provided by a medium- or large-scale security vendor in Japan (according to NRI Secure research).|
|*2||Blockchain technology: A technology which achieves a distributed consensus among its participants and makes it possible to manage audit trails for all transactions, without the intervention of a trusted third party. Given such features as its ability to make falsifying data extremely difficult, its near-zero downtime, its lack of a centralized manager, and its high transaction performance, the blockchain has been lauded for being inexpensive to develop and for its potentially broad application as a way for companies to exchange information. These features have led to expectations that the blockchain can be used not only for cryptocurrencies such as Bitcoin, but as a circulation platform for transactions involving various asset types. Furthermore, this technology is also gaining notice for its potential use in the recording and storage of more common types of contracts, as well as in automatic contract execution.|
|*3||Smart contracts: This refers to contracts which are programmed and can be automatically executed. A smart contract is arranged with the execution conditions and contractual terms prescribed in advance, such that the contract is automatically executed when a transaction occurs matching said conditions. Smart contracts are being considered for use in securities settlements, real property transactions, the sharing economy, and numerous other fields that involve contracts.|
|*4||Actual damage: “The DAO Incident” occurred on June 17, 2016. Funds (virtual currency) held by “The DAO,” a virtual corporation established by a Germany-based venture capital company, were transmitted to a cyber-attacker who had exploited vulnerabilities in The DAO’s smart contract programming code.|
|*5||DApps: This abbreviation stands for Decentralized Applications, and refers to applications that are decentralized and distributed. They are said to enable the use of highly-reliably, low-cost applications via blockchain technology, without the need for a centralized system manager.|
About NRI Secure
NRI SecureTechnologies is a subsidiary of Nomura Research Institute
(NRI) specializing in Cybersecurity, and a leading global provider of
next-generation managed security services and security consulting.
Established in 2000, NRI SecureTechnologies is focused on delivering
high-value security outcomes for our clients with the precision and
efficiency that define Japanese quality.
For more details, visit us at http://www.nri-secure.com
“Blockchain Assessment” Service
Supported platforms: Ethereum, Hyperledger Fabric
*Additional platforms will be supported at a later time.
Supported languages: Solidity, Go, Java
*Please contact us regarding any other languages.
- Price: Estimates will be provided on an individual basis.
- For more details on the “Blockchain Assessment” Service, please contact: firstname.lastname@example.org.
NRI SecureTechnologies, Ltd.
Hitomi Nemoto, +81-3-6706-0622
NRI SecureTechnologies, Ltd.
Teruhiro Tagomori / Takenori Kiuchi, +81-3-6706-0622
Cyber Security Services Department II
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30111.12.2017 09:30 | Tiedote
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 09:00 | Tiedote
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 08:01 | Tiedote
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials11.12.2017 01:45 | Tiedote
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 18:30 | Tiedote
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 18:30 | Tiedote
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme